Shanghai Fosun Pharmaceutical (02196) granted a total of 4,535,100 A shares options.

Shanghai Fosun Pharmaceutical (02196) announced that 6 of the initial grant recipients identified in the 2025 A-share stock option incentive plan are no longer working for the group and are no longer within the scope of this incentive plan. As authorized by the shareholders' meeting, approved by the board of directors, and verified by the board of directors' remuneration and assessment committee, adjustments have been made to the list of initial grant recipients and the number of A-share options involved: the number of initial grant recipients has been adjusted from 201 to 195, and the number of A-share options granted for the initial grant has been adjusted from 4.5809 million to 4.5351 million. On November 4, 2025, a total of 4.5351 million A-share options have been granted to 195 incentive recipients, with an exercise price of RMB 27.93 per share.